This is a type of nerve growth that causes a soft, spongy bump under the skin. It often happens on the face, neck, or chest. It's usually linked to a condition called Neurofibromatosis 1, and it can grow larger over time.
Every report comes from a Lived member, sent anonymously.
Have you tried Gomekli (Mirdametinib) for Plexiform Neurofibroma?
A plexiform neurofibroma is a noncancerous tumor that grows along a nerve and spreads into its branches, forming a mass that can be large, irregular and woven through the surrounding tissue. The word plexiform describes this network-like growth. The tumor starts in the cells that wrap and support nerves, so it can arise almost anywhere in the body, from the face and neck to the chest, abdomen, pelvis and limbs. Plexiform neurofibromas are closely tied to neurofibromatosis type 1 (NF1), a genetic condition that causes tumors to form on nerves. About 3 in 10 people with NF1 have one that can be seen or felt, and whole-body scans find them in up to half. Some lie under the skin and change the shape of the face or a limb, often with thickened, darker skin over them. Others sit deep inside the body and cause no symptoms for years. When they do cause problems, pain is the most common, along with changes in appearance, weakness or numbness, and pressure on nearby organs, the airway or the spinal cord. A small but important share can turn into a cancer called a malignant peripheral nerve sheath tumor (MPNST), which is why ongoing monitoring matters.
Plexiform neurofibromas develop because of changes in the NF1 gene. This gene normally makes a protein, neurofibromin, that acts as a brake on cell growth. People with NF1 carry one altered copy of the gene in every cell. A tumor forms when the second copy also stops working in a nerve-supporting cell, leaving a growth signal switched on. About half of people with NF1 inherited it from a parent; the other half have a new gene change that neither parent carries. Once someone has NF1, they can pass it on to their children. Many plexiform neurofibromas are present at birth or appear in the first years of life. They tend to grow fastest in young children and more slowly in teenagers and adults, and in adults some internal tumors even shrink on their own over time. There is little evidence that puberty, pregnancy or hormonal birth control drive their growth. Nothing a person or parent did causes these tumors, and there is no known way to prevent them. Some people have a higher chance that a tumor will become cancerous. Higher-risk features include many or large internal plexiform neurofibromas, a previous atypical neurofibroma (a tumor that looks partway between benign and malignant under the microscope), earlier radiation therapy, certain specific NF1 gene changes, and a relative with NF1 who developed an MPNST.
Many plexiform neurofibromas are first noticed during a physical exam by a clinician experienced in NF1, who looks and feels for a soft, irregular swelling, uneven growth of the face or a limb, or thickened, darker skin. A single plexiform neurofibroma counts as one of the formal diagnostic criteria for NF1, so finding one in someone without a known diagnosis usually leads to a full NF1 evaluation, often including genetic testing. MRI (magnetic resonance imaging) is the main test. It shows how far the tumor extends along nerves and how close it lies to vital structures, and repeated scans show whether it is growing. Ultrasound can add information about tumors near the surface. Because many tumors are deep and silent, European NF1 guidelines suggest a whole-body MRI at least once around the move from adolescence to adulthood, to gauge how much internal tumor there is and plan follow-up accordingly. When a tumor shows signs of turning cancerous, testing goes further: a focused MRI, often a positron emission tomography (PET) scan (which highlights tissue taking up unusually large amounts of sugar), and then a biopsy or surgical removal to examine the tissue. A biopsy may need several samples, because cancerous areas within a large tumor can be patchy.
Treatment depends on whether a tumor causes symptoms, where it sits and whether it can be removed safely. A plexiform neurofibroma that is stable and causing no problems is usually watched rather than treated. Decisions are best made with a team experienced in NF1 that includes surgeons, oncologists and other specialists. Surgery is the only treatment that can potentially remove a plexiform neurofibroma for good. It works best for a tumor that can be taken out without damaging important nerves or organs. In practice, the network-like growth often makes complete removal impossible, particularly in the head and neck, and the part left behind can grow back, especially in children and young adults. Partial removal may still be worthwhile to relieve pain, pressure or disfigurement. For tumors that cause symptoms and cannot be fully removed, two oral medicines taken twice a day are approved in the US. Called MEK inhibitors, they block MEK, a protein that relays the growth signal left switched on when NF1 is not working. Both are approved for adults as well as children: selumetinib (Koselugo) from age 1 and mirdametinib (Gomekli) from age 2. In clinical trials, these medicines shrank the tumor by at least a fifth of its volume in roughly 4 to 7 in 10 children and about 2 to 4 in 10 adults, depending on the study, and many people had less pain. They rarely make a tumor disappear, shrinkage usually takes several months to show, and treatment often continues for years. The trade-offs are real. Rash, acne-like skin changes, infections around the nails and diarrhea are common. Because these medicines can weaken the heart's pumping and affect the retina, people taking them have regular heart ultrasounds and eye exams. They can harm a developing pregnancy, so effective contraception is needed during treatment and for a while after stopping, including for men whose partner could become pregnant. Pain management, physical and occupational therapy, and psychological support are also part of care, since pain and visible changes can weigh heavily on daily life and self-image.
Plexiform neurofibromas behave very differently from one person to the next. Some stay small and silent for life. Others grow during childhood, then slow down or stop in adulthood. A tumor in the face or around the eye can affect appearance and vision, one near the spine or in a limb can affect strength and movement, and one in the neck or chest can press on the airway. Pain is the symptom people most often live with. Follow-up is lifelong. European NF1 guidelines suggest a check by an NF1-experienced clinician at least yearly until about age 10, at least every two years in older children and at least every three years in adults, with more frequent visits when a tumor needs closer watching. MRI timing depends on how a tumor is behaving: a new, growing or symptomatic tumor is often scanned every 3 to 6 months, and a stable one about once a year. Photos or videos can help track visible changes between visits. The main long-term concern is cancer. Across everyone with NF1, the lifetime chance of developing an MPNST has been estimated at about 16 in 100, and it tends to appear at a younger age than in people without NF1. Surgery is the main treatment for MPNST, so knowing the warning signs and keeping up with monitoring are the best ways to catch one early. Living with a visible or painful tumor and an uncertain outlook can be stressful for patients and families, and NF1 guidelines recommend psychological support as a routine part of care.
Arrange an evaluation with an NF1-experienced clinician if you or your child has NF1 and notice a new swelling, an area of thickened or darker skin, or uneven growth of the face or a limb, or if a known tumor starts to affect comfort, appearance or function. Contact the care team promptly, for an exam and imaging rather than waiting for the next routine visit, if a plexiform neurofibroma becomes newly or persistently painful, hurts at night, causes pain that is hard to control, grows quickly, develops a hard lump within a previously soft area, or causes new weakness, numbness or trouble swallowing. These can be signs of a change toward cancer. People taking a MEK inhibitor should also report blurred vision or other changes in sight, and a rash that is spreading or severe. Seek emergency care for sudden or rapidly worsening difficulty breathing, or for sudden weakness of the arms or legs or loss of bladder or bowel control, since a tumor pressing on the airway or spinal cord can cause lasting harm.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Plexiform Neurofibroma is like, what's helped you, or ask the community a question.